Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,472,218 | $1,786,562 | $1,922,768 | $699,878 |
| - Cash | $517,553 | $137,636 | $298,395 | $171,445 |
| + Debt | $3,188 | $3,557 | $3,894 | $3,894 |
| Enterprise Value | $1,957,853 | $1,652,483 | $1,628,267 | $532,327 |
| Revenue | $491,734 | $398,204 | $214,203 | $140,833 |
| % Growth | 23.5% | 85.9% | 52.1% | – |
| Gross Profit | $422,889 | $346,237 | $179,810 | $118,949 |
| % Margin | 86% | 86.9% | 83.9% | 84.5% |
| EBITDA | $232,898 | $119,693 | $103,077 | $52,577 |
| % Margin | 47.4% | 30.1% | 48.1% | 37.3% |
| Net Income | $163,889 | $71,410 | $83,079 | $39,482 |
| % Margin | 33.3% | 17.9% | 38.8% | 28% |
| EPS Diluted | 1.31 | 0.63 | 0.75 | 0.37 |
| % Growth | 107.9% | -16% | 102.7% | – |
| Operating Cash Flow | $239,808 | $143,600 | $116,047 | $60,372 |
| Capital Expenditures | -$556 | -$81,744 | -$29 | -$1,021 |
| Free Cash Flow | $239,252 | $61,856 | $116,018 | $59,351 |